Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Clinical trial NCT05546580 · UNKNOWN

Trial details

NCT number: NCT05546580
Sponsor: Oryzon Genomics S.A.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory

Start date: 2022-11-14
Primary completion: 2025-11-30
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.